Spero Therapeutics, Inc. Retained Earnings
Spero Therapeutics, Inc. (SPRO) had Retained Earnings of -$467.82 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$467.82M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$458.27M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$451.07M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$482.59M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$467.82M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$458.27M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$451.07M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$482.59M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$475.20M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$473.50M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$459.64M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$438.75M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$421.60M 10-Q · filed 2024-08-05 |
| 2024-03-31 | -$403.74M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$391.07M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$442.26M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$439.06M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$427.14M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$413.88M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$440.65M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$428.97M 10-Q · filed 2022-08-10 |
| 2022-03-31 | -$400.29M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$367.46M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$338.22M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$315.70M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$297.13M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$277.71M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$259.12M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$240.19M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$222.69M 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$199.43M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$174.44M 10-Q · filed 2019-11-04 |
| 2019-06-30 | -$156.72M 10-Q · filed 2019-08-08 |
| 2019-03-31 | -$143.57M 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$138.50M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$127.90M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$117.44M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$107.48M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$96.84M 10-K · filed 2019-03-14 |
| 2017-09-30 | -$82.19M 10-Q · filed 2017-12-14 |
| 2016-12-31 | -$45.44M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |